Disruption of the inner ear can lead to sudden hearing loss and / or ear noise and / or dizziness. To date, the exact cause of the so-called hearing loss is not known. It only seems to be certain that the sensory cells are under stress and therefore no longer function properly.
The treatment is less consistent and partly controversial. HEAD CENTER therefore analyzes the treatment results in a separate section, compares them with the international publications and adjusts the treatment as needed.
In the current S1 guideline of the Association of Scientific Medical Societies (AWMF), a high-dose glucocorticoid therapy is recommended as an intravenous infusion and / or injection directly into the middle ear in an acute hearing loss (as of April 2021).
Nevertheless, this treatment is not taken over by the statutory health insurance funds without risk of regress for the doctor and can only be provided as an individual health service. This situation has been criticized by the professional association and ENT specialist for years. Because, there are undoubtedly results that justify the use of a systemic intravenous high-dose glucocorticoid therapy. We assure you to settle all billable services around the therapy with your health insurance and thus to keep your costs as low as possible.
IOP = intravenous infusion of methylprednisolone, on 2 days in the practice.
250 mg of Urbason® is administered intravenously on each of 2 consecutive days. The effect occurs within 48 hours and can improve the function of the inner ear within 4 weeks. Note: In case of discontinuation of the therapy, the costs cannot be reimbursed - even proportionally.